Brief: Stayble Therapeutics Resolves On Rights Issue Of About SEK 35.2 Mln

Stayble Therapeutics AB

23/02/2023 08:49

Feb 23 (Reuters) - Stayble Therapeutics AB   STABL.ST :
    * SAID ON WEDNESDAY RESOLVES ON NEW ISSUE OF SHARES WITH
PREFERENTIAL RIGHTS FOR CO'S EXISTING SHAREHOLDERS
    * SUBSCRIPTION PRICE FOR RIGHTS ISSUE IS SET AT SEK 1.78 PER
SHARE
    * RIGHTS ISSUE WILL, IF FULLY SUBSCRIBED, RAISE ABOUT SEK
35.2
MLN, BEFORE ISSUE COSTS
    * DECISION SUBJECT TO EGM APPROVAL
    * ABOUT 11.7% OF RIGHTS ISSUE IS COVERED BY SUBSCRIPTION
WARRANTS,
ABOUT 38.3% BY BOTTOM GUARANTEE, ABOUT 30% BY TOP GUARANTEE
    * RIGHTS ISSUE IS GUARANTEED UP TO 80%
    * PURPOSE OF RIGHTS ISSUE IS TO PROVIDE CO WITH WORKING
CAPITAL
AND TO INITIATE A PHASE 1B STUDY WITH THE DRUG CANDIDATE STA363

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr9vv9GZ
 Further company coverage:  STABL.ST  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))